47 results about "A Antibody" patented technology

The present disclosure relates to a pyrrolo benzodiazepine derivative and a conjugate, preparation method and use thereof. In particular, the present disclosure relates to a compound of formula (DL) and a antibody-drug conjugate thereof, a pharmaceutical composition containing same, and a use thereof in the preparation of a medicament for the treatment of cancer. The definitions of groups in the general formula (DL) are as defined in the description.

The invention discloses a preparation method and application of a quail CENP-A polyclonal antibody, and the preparation method of the quail CENP-A polyclonal antibody comprises the following steps: constructing a recombinant expression vector containing a CENP-A target gene segment as shown in SEQ ID NO.1; transforming the recombinant expression vector into a competent cell, inducing expression of a fusion protein, collecting and purifying to obtain a CENP-A recombinant protein; carrying out animal immune treatment by taking the CENP-A recombinant protein as an antigen, and collecting and separating an antibody in animal serum as a CENP-A polyclonal antibody. The invention also develops a method and a device for CUAMP; the quail CENP-A antibody sequenced by Tag fills up the blank of a quail commercial CENP-A antibody, is also an important basic work for further constructing a quail genome complete map, and provides a basic support for subsequently revealing how centromere related genes of vertebrates such as birds evolve among different species.

The invention relates to a B cell specific light chain detection kit, and belongs to the technical field of biology. The B cell specific light chain detection kit comprises an antibody composition, a fixing agent and a permeabilized buffer solution, the antibody composition comprises an A group antibody and a B group antibody, wherein the A group antibody comprises an anti-Kappa antibody and an anti-Lambda antibody; the group B antibody comprises an anti-CD19 antibody, an anti-CD38 antibody, an anti-CD5 antibody, an anti-CD10 antibody, an anti-CD20 antibody and an anti-CD45 antibody; the permeabilization buffer solution comprises amino acid modified saponin. And the contained permeabilized buffer solution is modified by amino acid, so that the permeability of cell membranes can be ensured, the cell morphology cannot be excessively damaged, and the accuracy of B cell specific light chain detection is improved.

Provided in the present disclosure are a multi-specific antibody or antigen-binding fragment, a composition, a preparation method and the use. By means of comprehensively considering interfacial amino acid interactions, amino acid pair mutations are introduced into CH1 and CL domains of a antibody, thereby improving correct pairing between a heavy chain and a light chain in the multi-specific antibody or antigen-binding fragment.

The present disclosure provides a pharmaceutical composition which comprises an anti-IL-31 receptor A antibody as an active ingredient thereof, and which is for the treatment of perforating dermatosis.

The present invention includes a method and kit for method for detecting anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease without performing a lip biopsy comprising: obtaining a biological sample from a patient suspected of having an anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease; and detecting if the biological sample has autoantibodies to at least one of: Geminin DNA Replication Inhibitor (GMNN), Kelch Domain Containing 8 A (KLHDC8A), Microtubule Associated Protein RP / EB Family Member 1 (MAPRE1), Nucleoporin 50 (NUP50), or SKI Like Proto-Oncogene (SKIL).

Provided in the present disclosure are a multi-specific antibody or antigen-binding fragment, a composition, a preparation method and the use. By means of comprehensively considering interfacial amino acid interactions, amino acid pair mutations are introduced into CH1 and CL domains of a antibody, thereby improving correct pairing between a heavy chain and a light chain in the multi-specific antibody or antigen-binding fragment.

Provided herein are anti-PAPP-A antibodies. Also provided are methods of using such antibodies to treat PAPP-A related disorders, such as kidney disease.

Disclosed is an antibody that specifically recognizes and binds to folate receptor α, also referred to as anti-folate receptor a antibody or anti-FRα antibody. Also disclosed is an antibody-drug conjugate of the anti-FRα antibody. Disclosed are uses of the anti-FRα antibody and the antibody-drug conjugate in the treatment of diseases related to FRα expression.

The invention relates to a preparation method and application of hybridoma cells based on an electrofusion technology, the preparation method of the hybridoma cells based on the electrofusion technology comprises the following steps: taking splenocytes and myeloma cells of an antigen-immunized mouse for electrofusion, screening to obtain the hybridoma cells, and the antigen is serum amyloid protein A. The invention also relates to a preparation method of the hybridoma cells based on the electrofusion technology. The hybridoma cell capable of generating the serum amyloid protein A antibody is obtained in an electrofusion mode, the fusion efficiency of the hybridoma cell is improved, and the problem that the yield of the antibody is reduced due to the fact that the fusion efficiency of the hybridoma cell is low is solved.

The present application relates to a fusion protein and its application in detection of Helicobacter pylori CagA antibody, and belongs to the technical field of biology.The present application provides a fusion protein, wherein the fusion protein comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO.1, or a derivative polypeptide with more than 80% homology with the amino acid sequence as shown in SEQ ID NO.1 and capable of being specifically combined with Helicobacter pylori CagA antibody; the fusion protein is capable of being specifically combined with Helicobacter pylori CagA antibody, and has a very high application prospect in detection of Helicobacter pylori CagA antibody.

The invention provides a helicobacter pylori virulence protein Cag A antigen, a helicobacter pylori virulence protein Cag A antibody and application of the helicobacter pylori virulence protein Cag A antigen and the helicobacter pylori virulence protein Cag A antibody. According to the invention, sequence analysis and combined screening are carried out on the antigen epitopes related to Cag A to obtain the Cag A antigen of a recombinant expression specific sequence, and the stability and specificity of the Cag A antigen are ensured. The invention also constructs a group of monoclonal antibodies specifically combined with the antigen based on the high-sensitivity Cag A antigen. The helicobacter pylori virulence protein Cag A antigen has relatively strong binding capacity with a Cag A antibody in a clinical sample, has relatively high detection sensitivity, can be combined with a specific antibody to serve as a raw material combination of a detection reagent, and has clinical detection superiority.

The present invention belongs to the technical field of pathogen detection, and specifically relates to an ELISA antibody detection kit for bovine Pasteurella multocida capsule type A, and its preparation method and application. The gene with the sequence shown in SEQ ID NO.1 is integrated into an expression vector and transferred into a host bacterium; the host bacterium is induced to express and purified to obtain a PmA153 recombinant antigen protein with the sequence shown in SEQ ID NO.2; PmA153 is coated on a solid phase carrier, and the detection method of bovine Pasteurella multocida capsule type A antibodies in the sample can be used to detect the bovine Pasteurella multocida capsule type A antibodies, thereby achieving the diagnostic purpose. The kit provided by the present invention does not use Pasteurella multocida as an antigen source, has good biosafety and low production costs, has good specificity for the detection of bovine Pasteurella multocida capsule type A antibodies, can accurately diagnose bovine Pasteurella multocida capsule type A pneumonia, and has important clinical application value.

1. The material of the article to which this design relates is synthetic resin. 2. The article to which this design relates is a set of teaching tools that can be used to learn about ABO blood types and RhD blood types. 3. Teaching tool A represents red blood cells, teaching tool B represents type A antigens, teaching tool C represents type B antigens, teaching tool D represents RhD antigens, teaching tool E represents anti-type A antibodies, teaching tool F represents anti-type B antibodies, and teaching tool G represents anti-RhD antibodies. 4. The article to which this design relates is designed to easily explain the phenomenon of red blood cells and the antigens present on their surfaces reacting with antibodies in serum. 5. Reference Figures 1 to 3 show the product in use. Reference Figure 1 shows that when type B red blood cells are reacted with a type A person, the anti-B antibodies in the type A serum and the type B red blood cells agglutinate. Reference Figure 2 shows that when type A red blood cells are reacted with a type B person, the anti-A antibodies in the type B serum and the type A red blood cells agglutinate. Reference Figure 3 shows the RhD phenomenon, where red blood cells with RhD antigens on their surface agglutinate with anti-RhD antibodies.

Provided are antibody-drug conjugates that specifically bind to B7H3 and pharmaceutical compositions comprising the same, as well as methods and uses of using the antibody-drug conjugates.

The invention belongs to the technical field of antigen recognition, and particularly relates to an antibody for targeted recognition of mCD155 or an antigen binding fragment thereof and application thereof. The antibody for targeted recognition of mCD155 comprises a sequence as shown in SEQ ID NO: 8 and SEQ ID NO: 16 or a sequence as shown in SEQ ID NO: 24 and SEQ ID NO: 32. The binding capacity of the gene and mCD155-his protein is high; and the CAR-T cell constructed on the basis of the antibody has an excellent killing (apoptosis) effect on mCD155 mediated tumors.

There is provided, inter alia, an aqueous solution comprising (i) an antibody protein; and (ii) a antibody protein stabilizing mixture of arginine, methionine, and a C3 polyol.

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The application discloses a foot-and-mouth disease virus type A ELISA antibody detection kit and a preparation method and application thereof. The application determines a sequence of a foot-and-mouth disease virus type A GH loop epitope polypeptide and a non-specific combination of a foot-and-mouth disease virus type O, effectively solves the non-specific combination problem through sequence reduction, obviously reduces the detection sensitivity of the type A antibody after the reduction, further improves the detection sensitivity through a form of a multi-antigen peptide to display the polypeptide sequence. Finally, the polypeptide epitope combination, the antigen coated plate containing the polypeptide epitope combination and the ELISA antibody detection kit are determined. The total coincidence rate of the kit for detecting foot-and-mouth disease inactivated vaccine immune antibodies and negative serum is as high as 95% or more, but the positive detection rate of the kit for detecting foot-and-mouth disease synthetic peptide vaccine immune antibodies is obviously improved, and the cross reaction of the kit for detecting foot-and-mouth disease virus type O vaccine and pig foot-and-mouth disease virus type O inactivated vaccine immune antibodies is effectively reduced.

Provided herein are anti-PAPP-A antibodies, as well as methods of using such antibodies to treat PAPP-A-associated disorders, e.g., kidney disease.

The invention discloses a Napsin A biological fusion enzyme antibody with a signal protein tag and application, an amino acid sequence of a light chain variable region of an anti-human Napsin A antibody is shown as SEQ ID NO: 7, an amino acid sequence of a heavy chain variable region of the anti-human Napsin A antibody is shown as SEQ ID NO: 3, the signal protein tag HRP is inserted into the N end of a light chain of the anti-human Napsin A antibody, and the amino acid sequence of the light chain variable region of the obtained HRP-Napsin A antibody is shown as SEQ ID NO: 5. In addition, the invention also provides a preparation method of the HRP-Napsin A antibody, the HRP-Napsin A antibody is a molecule completely secreted along with the antibody, has no heterogeneity, is good in sensitivity, high in specificity and stable in performance, and does not need to add a secondary antibody during detection, so that the cost is saved, and the efficiency is improved.

To provide novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto; and to provide polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies.SOLUTION: Provided is a human-derived recombinant monoclonal anti-Nogo-A antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof binding to the Nogo-A-Δ20 domain and being capable of inducing dose-dependent neurite outgrowth and / or angiogenesis in stroke penumbra.SELECTED DRAWING: None

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof.

The present disclosure provides methods for treating neurological disorders (e.g., trauma of peripheral nervous system (PNS) or central nervous system (CNS)) using anti- Nogo-A antibodies or antigen-binding fragments thereof.

The present invention relates to methods of treating ovarian cancer in a subject by administering to the subject by evaluating the subject's expression levels of specific biomarkers or angiogenic an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In some embodiments, at least two compounds are administered to the subject, where the first compound is an anti-activin A compound, and the second compound is a chemotherapeutic compound, for example capecitabine. The invention further relates to methods of identifying subjects for treatment factors.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

The present invention relates to an anti-human interleukin-4 receptor A antibody, a pharmaceutical composition thereof or a kit, and an application thereof in the treatment of eosinophilic esophagitis.

The utility model discloses an antibody sterile culture device which is applied to the field of antibody culture and comprises a culture box, a hot air drying mechanism is arranged at the upper end of the culture box, a supporting frame is arranged in the culture box, a through groove is formed in the supporting frame, a fixing groove is formed in the supporting frame, and the through groove is communicated with the through groove. By arranging the incubator body, the hot air drying mechanism, the supporting frame, the through grooves, the fixing grooves and the culture dishes, during use, after the interior of the incubator body is cleaned, the interior of the incubator body can be rapidly dried through the hot air drying mechanism, and the drying efficiency of the incubator body is improved; then the fixing grooves in the supporting frames can fix the culture dishes, then the antibodies can be conveniently cultured in the culture dishes, then when the interior of the incubator is dried, the through grooves can enable the cleaning water to flow down, and then the cleaning water can be conveniently discharged.

The present invention relates to an anti-human interleukin-4 receptor A antibody, a pharmaceutical composition thereof or a kit, and an application thereof in the treatment of eosinophilic esophagitis.